New patent approved on the US market
AroCell announces today that the US Patent Office has approved and issued AroCell's patent US 11,959,919 B2, entitled "Predicting cancer progression".
The patent is one of AroCell's early patents that demonstrated the clinical significance of serum TK1 protein measurements using the specific antibodies against the C-terminal region of TK1 in cancer. This patent extends a previously approved European patent with the number EP 1,627,230 B1. The new patent is now valid until 2034.